Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M

Apyx Medical Corp

Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.
Q4 net loss narrowed to $1.3M ($0.03/sh) from $4.6M ($0.12/sh); Adjusted EBITDA $0.7M vs ($2.2M).
FY2025 total revenue $52.8M (+9.9% YoY); net loss $11.2M ($0.27/sh) vs $23.5M ($0.66/sh) in 2024.
FY2026 guidance: total revenue $57.5M-$58.5M; Surgical Aesthetics rev $53M-$54M; OEM rev ~$4.5M.
Submitted 510(k) for AYON power liposuction label expansion; clearance anticipated mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.